JNJ ▲ +0.1% - Johnson & Johnson
$JNJ - Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
25-SEP-2026 07:30 AM ET
Share this post
More filings for $JNJ
JNJ ▲ +0.1% - Johnson & JohnsonSep 25, 2026JNJ ▲ +0.1% - Johnson & JohnsonSep 25, 2026JNJ ▲ +0.3% - Johnson & JohnsonSep 23, 2026JNJ ▲ +0.4% - Johnson & JohnsonSep 15, 2026JNJ ▼ -1.6% - Johnson & JohnsonSep 8, 2026JNJ ▲ +1.4% - Johnson & JohnsonSep 2, 2026
View full $JNJ filing history →💬 Comments
Loading comments…
Leave a comment